Mohammad Jamal Mohammad Alzghari, MD in Des Moines, IA - Medicare

Mohammad Jamal Mohammad Alzghari, MD is a medicare enrolled "Transplant Surgery" physician in Des Moines, Iowa. His current practice location is 1212 Pleasant St Ste 211, Des Moines, Iowa. You can reach out to his office (for appointments etc.) via phone at (515) 283-1541.

Mohammad Jamal Mohammad Alzghari is licensed to practice in Iowa (license number MD-49565) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1588076962.

Contact Information

	Mohammad Jamal Mohammad Alzghari, MD
	1212 Pleasant St Ste 211, Des Moines, IA 50309-1411
	(515) 283-1541
	(515) 283-0473

Physician's Profile

Full Name	Mohammad Jamal Mohammad Alzghari
Gender	Male
Speciality
Experience	Years
Location	1212 Pleasant St Ste 211, Des Moines, Iowa
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Mohammad Jamal Mohammad Alzghari attended and graduated from in

NPI Data:

NPI Number: 1588076962
Provider Enumeration Date: 05/20/2014
Last Update Date: 07/17/2023

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Mohammad Jamal Mohammad Alzghari such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1588076962	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208600000X	Surgery	MD-49565 (Iowa)	Secondary
204F00000X	Transplant Surgery	MD-49565 (Iowa)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mohammad Jamal Mohammad Alzghari is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mohammad Jamal Mohammad Alzghari, MD 5950 University Ave Ste 321, West Des Moines, IA 50266-8289 Ph: (515) 875-9100	Mohammad Jamal Mohammad Alzghari, MD 1212 Pleasant St Ste 211, Des Moines, IA 50309-1411 Ph: (515) 283-1541

News Archive

Study on miscarriage rates following IVF treatment with frozen thawed embryos

Elsevier, a world-leading provider of scientific, technical and medical information products and services today announced the publication of an article in the December issue of Reproductive BioMedicine Online (www.rbmonline.com) about miscarriage rates following IVF treatment with frozen thawed embryos which may revolutionize clinical and laboratory practice.

Mediterranean ketogenic diet can help alter fungi in the gut linked to Alzheimer's risk

Specific fungi in the gut associated with a higher risk of Alzheimer's disease and found in people with mild cognitive impairment (MCI) can be altered in a beneficial manner by eating a modified Mediterranean diet, researchers at Wake Forest School of Medicine have found.

Study explores the nature and robustness of support networks in old age

Being able to grow old and die in one's own home is something people want, including those who live alone. Behind the life situation of the latter one finds many different relationship constellations and support networks.

West Nile virus prevention

Whether you're hitting the hiking trail, barbecuing in the back yard, or camping out in the great outdoors, you'll want to protect against mosquito bites.

Phase 1 clinical trial of OXY111A initiated

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.

Mohammad Jamal Mohammad Alzghari, MD - Medicare in Des Moines, IA